125 related articles for article (PubMed ID: 31853942)
1. Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse-preventive immunotherapy in acute myeloid leukaemia.
Nilsson MS; Hallner A; Brune M; Nilsson S; Thorén FB; Martner A; Hellstrand K
Br J Haematol; 2020 Feb; 188(4):e49-e53. PubMed ID: 31853942
[No Abstract] [Full Text] [Related]
2. Dynamics of myeloid cell populations during relapse-preventive immunotherapy in acute myeloid leukemia.
Rydström A; Hallner A; Aurelius J; Sander FE; Bernson E; Kiffin R; Thoren FB; Hellstrand K; Martner A
J Leukoc Biol; 2017 Aug; 102(2):467-474. PubMed ID: 28235771
[TBL] [Abstract][Full Text] [Related]
3. Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia.
Sander FE; Rydström A; Bernson E; Kiffin R; Riise R; Aurelius J; Anderson H; Brune M; Foà R; Hellstrand K; Thorén FB; Martner A
Oncotarget; 2016 Feb; 7(7):7586-96. PubMed ID: 26863635
[TBL] [Abstract][Full Text] [Related]
4. NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance.
Martner A; Rydström A; Riise RE; Aurelius J; Brune M; Foà R; Hellstrand K; Thorén FB
Oncotarget; 2015 Dec; 6(40):42569-74. PubMed ID: 26544512
[TBL] [Abstract][Full Text] [Related]
5. Early related or unrelated haematopoietic cell transplantation results in higher overall survival and leukaemia-free survival compared with conventional chemotherapy in high-risk acute myeloid leukaemia patients in first complete remission.
Basara N; Schulze A; Wedding U; Mohren M; Gerhardt A; Junghanss C; Peter N; Dölken G; Becker C; Heyn S; Kliem C; Lange T; Krahl R; Pönisch W; Fricke HJ; Sayer HG; Al-Ali H; Kamprad F; Niederwieser D;
Leukemia; 2009 Apr; 23(4):635-40. PubMed ID: 19151786
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapy with histamine dihydrochloride for the prevention of relapse in acute myeloid leukemia.
Martner A; Thorén FB; Aurelius J; Söderholm J; Brune M; Hellstrand K
Expert Rev Hematol; 2010 Aug; 3(4):381-91. PubMed ID: 21083028
[TBL] [Abstract][Full Text] [Related]
7. Improved leukemia-free survival after postconsolidation immunotherapy with histamine dihydrochloride and interleukin-2 in acute myeloid leukemia: results of a randomized phase 3 trial.
Brune M; Castaigne S; Catalano J; Gehlsen K; Ho AD; Hofmann WK; Hogge DE; Nilsson B; Or R; Romero AI; Rowe JM; Simonsson B; Spearing R; Stadtmauer EA; Szer J; Wallhult E; Hellstrand K
Blood; 2006 Jul; 108(1):88-96. PubMed ID: 16556892
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype.
Nilsson MS; Hallner A; Brune M; Nilsson S; Thorén FB; Martner A; Hellstrand K
Hum Vaccin Immunother; 2020; 16(1):109-111. PubMed ID: 31242079
[TBL] [Abstract][Full Text] [Related]
9. Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.
Jahic A; Iljazovic E; Hasic S; Arnautovic AC; Sabitovic D; Mesanovic S; Sahovic H; Simendic V
Med Arch; 2017 Feb; 71(1):20-24. PubMed ID: 28428668
[TBL] [Abstract][Full Text] [Related]
10. Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy.
Sander FE; Nilsson M; Rydström A; Aurelius J; Riise RE; Movitz C; Bernson E; Kiffin R; Ståhlberg A; Brune M; Foà R; Hellstrand K; Thorén FB; Martner A
Cancer Immunol Immunother; 2017 Nov; 66(11):1473-1484. PubMed ID: 28721449
[TBL] [Abstract][Full Text] [Related]
11. The outcome of sibling and unrelated donor allogeneic stem cell transplantation in adult patients with acute myeloid leukemia in first remission who were initially refractory to first induction chemotherapy.
Cook G; Clark RE; Crawley C; Mackinnon S; Russell N; Thomson K; Pearce RM; Towlson K; Marks DI
Biol Blood Marrow Transplant; 2006 Mar; 12(3):293-300. PubMed ID: 16503498
[TBL] [Abstract][Full Text] [Related]
12. Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance.
Grauers Wiktorin H; Aydin E; Christenson K; Issdisai N; Thorén FB; Hellstrand K; Martner A
Oncoimmunology; 2021; 10(1):1944538. PubMed ID: 34367728
[TBL] [Abstract][Full Text] [Related]
13. Histamine dihydrochloride and low-dose interleukin-2 as post-consolidation immunotherapy in acute myeloid leukemia.
Thorén FB; Romero AI; Brune M; Hellstrand K
Expert Opin Biol Ther; 2009 Sep; 9(9):1217-23. PubMed ID: 19653866
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy of acute myeloid leukaemia. Medical Research Council.
Br J Cancer; 1978 Jan; 37(1):1-14. PubMed ID: 339940
[TBL] [Abstract][Full Text] [Related]
15. Effectivity of a strategy in elderly AML patients to reach allogeneic stem cell transplantation using intensive chemotherapy: Long-term survival is dependent on complete remission after first induction therapy.
von dem Borne PA; de Wreede LC; Halkes CJ; Marijt WA; Falkenburg JH; Veelken H
Leuk Res; 2016 Jul; 46():45-50. PubMed ID: 27123833
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614).
Yin J; LaPlant B; Uy GL; Marcucci G; Blum W; Larson RA; Stone RM; Mandrekar SJ
Blood Adv; 2019 Jun; 3(11):1714-1721. PubMed ID: 31171508
[TBL] [Abstract][Full Text] [Related]
17. Feasibility of BAALC gene expression for detection of minimal residual disease and risk stratification in normal karyotype acute myeloid leukaemia.
Weber S; Haferlach T; Alpermann T; Perglerová K; Schnittger S; Haferlach C; Kern W
Br J Haematol; 2016 Dec; 175(5):904-916. PubMed ID: 27662611
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic haematopoietic cell transplantation for adult acute myeloid leukaemia in second remission: a retrospective study of the Adult Acute Myeloid Leukaemia Working Group of the Japan Society for Haematopoietic Cell Transplantation (JSHCT).
Konuma T; Yanada M; Yamasaki S; Kuwatsuka Y; Fukuda T; Kobayashi T; Ozawa Y; Uchida N; Ota S; Hoshino T; Takahashi S; Kanda Y; Ueda Y; Takanashi M; Kanda J; Ichinohe T; Atsuta Y; Yano S
Br J Haematol; 2018 Jul; 182(2):245-250. PubMed ID: 29808919
[TBL] [Abstract][Full Text] [Related]
19. A systematic overview of chemotherapy effects in acute myeloid leukaemia.
Kimby E; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):231-52. PubMed ID: 11441935
[TBL] [Abstract][Full Text] [Related]
20. Impact of early remission by induction therapy on allogeneic stem cell transplantation for acute myeloid leukemia with an intermediate-risk karyotype in first complete remission.
Hemmati PG; Terwey TH; Na IK; le Coutre P; Jehn CF; Vuong LG; Dörken B; Arnold R
Eur J Haematol; 2015 May; 94(5):431-8. PubMed ID: 25220715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
